Good Tuesday afternoon folks. Before we even get a chance to forget, look for a new trading idea in your inbox tomorrow (Wednesday) morning, right around the open. We mentioned in Monday afternoon's newsletter we were finalizing some thoughts on a new Featured Stock. We wrapped up that review today, and will have it in your hands early tomorrow. We're excited about it, particularly in light of the news the company shared this morning. We can't tell you any more about it right now, other than to let you know it's a junior gold mining stock, and now's the right time to be looking at gold stocks. See, we still contend gold is on the verge of a major bullish reversal, which is even better for large gold miners, and better still for small gold miners. You can see on the chart below how the VanEck Vectors Gold Miners ETF (GDX) outperformed the SPDR Gold Trust ETF (GLD) when gold took a turn for the better in January. The VanEck Vectors Junior Gold Miners ETF (GDXJ) decidedly outpaced its large-cap counterpart. And yes, we still have every reason to look for gold to rebound from here. We brought it up yesterday, but Tuesday's action merits another look. On the chart of the SPDR Gold Trust ETF and the U.S. Dollar Index below, you just get the sense gold is testing the waters of higher highs, and the dollar is setting up a sizeable pullback after an oversized October/November runup. Once such a reversal takes hold, it's likely to do so with a vengeance. That's not the only reason we've got a sneaking suspicion that the gold selloff has run its course. It's one of the big ones though. In any case, while we've got plans to add a new Featured Stock to the stable tomorrow morning, we've also got some existing trading ideas that need tending to. Both Sack Lunch Productions (SAKL) and Lexaria Bioscience (LXRP) had news worth a closer look today. In no certain order... Sack Lunch Productions reported its third quarter numbers today. They were good. They weren't as good as the third quarter numbers from a year earlier, but as James Brumley suggested in his comments about the report, the comparison may not have been an entirely fair one. Either way, the chart of the company's results for the past couple of years tells the tale. Revenue is trending higher. Gross profits are trending higher. Deferred revenue is trending higher. There's no denying it's a hot and cold history. That's just the nature of the beast - all of SAKL's events have to take place outside, and that means most of them require warmer weather. Over a twelve month span, it doesn't really matter when the revenue is booked and when the profits are banked. In any case, CEO Richard Surber said to look for another acquisition by the end of the first quarter of the coming year. If you're not familiar with Sack Lunch Productions, our very first look from May 31st is still the very best primer for newcomers. As for Lexaria Bioscience, today's news went a long way in answering the question "what can you do with an enhanced-absorption science?" One of the things LXRP is doing with it is adding a cannabinoid element to a health supplement that contains pterostilbene.... the healthiest component of blueberries. Just as a quick refresher, Lexaria has developed and patented a way of infusing hemp oil into a lipid as a means of improving its ingestion in the human body. See, all the vitamins, amino acids, probiotics, antioxidants, proteins, chondroitin, and everything else you might find in a health supplement aren't very well absorbed via the intestinal tract. Some of it makes its way into the blood stream and to.... wherever. Most of it, though, is never processed in the digestive system. Not only is it wasted money, users may well be missing out on something their body desperately needs. Lexaria Biosciences has a solution. Since the body processes lipids much better than it processes water-based supplements, infusing a lipid with hemp oil leads to far greater absorption of all the good things found in hemp. This botanical supplement can do some amazing things too,, like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more. And to be clear, we're talking about hemp, and not marijuana.... though it would work for marijuana too. In fact, the science can improve the bioavailability of a wide variety of compounds and molecules. The company's just starting with hemp, since that's where the biggest opportunity lies. Fast forward to today. This morning, Lexaria and supplement maker NeutriSci International (CVE:NU) announced they were teaming up to produce tablets that contain pterostilbene as well as hemp-infused oil, creating an easy-to-use supplement that many consumers have been patiently waiting for. NeutriSci gets access to a science that can make for a unique, highly marketable product, while Lexaria Bioscience gets the benefit of NeutriSci's existing distribution network. Matthew Briar has a closer look. This is just the first of many ways we expect to hear Lexaria's science can be commercialized. Here's our first look at LXRP from late October. Finally, while the market may have been up today, take it with a grain of salt. It's not like today was a real "running of the bulls" kind of moment. It was just as much a lack of bears putting up a fight, which for whatever reason we tend to see around holiday breaks. Yes, the S&P 500 put some distance between itself and a key ceiling at 2194. The Dow Jones Industrial Average also moved into new-high territory, and held above a key technical ceiling at 19,000. From just a superficial point of view, that has to be bullish. And yet, we just can't justify digging in too deep here. Maybe we're just being too pessimistic, and our apologies if that's the case. We'd just feel a whole lot better if the S&P 500 could peel back a little and touch the support around 2150 and then rekindle the uptrend. That would greatly validate this so-far-untested rally effort. In the meantime, we just have to be patient. Don't forget.... check your inbox tomorrow morning, right around the open.